Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | GFER | P55789 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21112853 | 0.87 | ALDH1A1 (0.51) | ALDH1A1GAASMN1; SMN2MAPTKMT2A | |
| SCHEMBL21112919 | 0.84 | MEN1 (0.54) | ALDH1A1AKR1C3SMN1; SMN2HTTGFER | |
| SCHEMBL21112890 | 0.84 | AKR1C3 (0.51) | ALDH1A1AKR1C3GAASMN1; SMN2MAPT | |
| SCHEMBL20873300 | 0.83 | TFPI2 (0.54) | ALDH1A1AKR1C3HTTMAPTKMT2A | |
| SCHEMBL21112897 | 0.79 | ALDH1A1 (0.57) | ALDH1A1AKR1C3SMN1; SMN2HTTMAPT | |
| SCHEMBL8324759 | 0.76 | SMN1; SMN2 (0.70) | L3MBTL1ALDH1A1AKR1C3GAASMN1; SMN2 | |
| SCHEMBL27976453 | 0.74 | AKR1C3 (0.85) | L3MBTL1ALDH1A1AKR1C3GAASMN1; SMN2 | |
| SCHEMBL21112927 | 0.72 | GAA (0.53) | L3MBTL1ALDH1A1AKR1C3GAASMN1; SMN2 | |
| SCHEMBL20873280 | 0.72 | PPP5C (0.44) | HTTLMNA | |
| SCHEMBL4182066 | 0.72 | L3MBTL1 (0.73) | L3MBTL1ALDH1A1AKR1C3GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210401946-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-12-30 | — | — | US | disclosed |
| US-20210401947-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-12-30 | — | — | US | disclosed |
| US-20210401947-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-12-30 | — | — | US | disclosed |
| US-11090364-B2 | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein | SANOFI (FR) | 2021-08-17 | — | — | US | disclosed |
| US-11090364-B2 | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein | SANOFI (FR) | 2021-08-17 | — | — | US | disclosed |
| US-20190209656-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2019-07-11 | — | — | US | disclosed |
| US-20190209656-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11090364-B2 | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein | GPR119, SLC2A8, SLC2A4 | L3MBTL1 4705/4885ALDH1A1 1514/4885AKR1C3 1463/4885 |
| US-20190209656-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | L3MBTL1 4705/4885ALDH1A1 1514/4885AKR1C3 1463/4885 |
| US-20210401946-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | L3MBTL1 4705/4885ALDH1A1 1514/4885AKR1C3 1463/4885 |
| US-20210401947-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | L3MBTL1 4705/4885ALDH1A1 1514/4885AKR1C3 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.